Comprehensive management of respiratory symptoms in patients with advanced lung cancer

Journal of Supportive Oncology

Volumn 10, Issue 1, 2012, Pages 1-8

  McCannon, Jessica ^a   Temel, Jennifer ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BENZODIAZEPINE; CROMOGLYCATE DISODIUM; DIHYDROCODEINE; ERLOTINIB; HYDROCODONE; LEVDROPROPIZINE; MIDAZOLAM; MORPHINE; PENTOXIFYLLINE; PLACEBO; PREDNISONE;

ADVANCED CANCER; ARTIFICIAL EMBOLISM; COUGHING; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEART TAMPONADE; HEMOPTYSIS; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG EMBOLISM; LUNG TOXICITY; MUSCLE RELAXATION; OXYGEN THERAPY; PATIENT CARE; PATIENT COUNSELING; PERICARDIOCENTESIS; PHYSICAL ACTIVITY; PLEURA EFFUSION; PNEUMONIA; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RADIATION PNEUMONIA; RELAXATION TRAINING; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; THORACOCENTESIS; TREATMENT OUTCOME;

EID: 84855815624     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2011.07.002     Document Type: Review

References (110)

1. Smith E.L., Hann D.M., Ahles T.A., et al. Dyspnea, anxiety, body consciousness, and quality of life in patients with lung cancer. J Pain Symptom Manage 2001, 21(4):323-329.
2. Edmonds P., Higginson I., Altmann D., et al. Is the presence of dyspnea a risk factor for morbidity in cancer patients?. J Pain Symptom Manage 2000, 19(1):15-22.
3. Kvale P.A. Chronic cough due to lung tumors: ACCP evidence-based clinical practice guidelines. Chest 2006, 129(suppl 1):147S-153S.
4. Hopwood P., Stephens R.J. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer 1995, 71(3):633-636.
5. Currow D.C., Smith J., Davidson P.M., et al. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life?. A consecutive cohort study. J Pain Symptom Manage 2010, 39(4):680-690.
6. Lutz S., Norrell R., Bertucio C., et al. Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital. J Palliat Med 2001, 4(2):157-165.
7. Vainio A., Auvinen A. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage 1996, 12(1):3-10.
8. Dudgeon D.J., Lertzman M. Dyspnea in the advanced cancer patient. J Pain Symptom Manage 1998, 16(4):212-219.
9. Hutten B.A., Prins M.H., Gent M., et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000, 18(17):3078-3083.
10. Hall I.E., Andersen M.S., Krumholz H.M., et al. Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol 2009, 2009:182521.
11. Meyer G., Marjanovic Z., Valcke J., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002, 162(15):1729-1735.
12. Lee A.Y., Levine M.N., Baker R.I., et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349(2):146-153.
13. Akl E.A., Barba M., Rohilla S., et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008, (2). CD006650.
14. Akl E.A., Rohilla S., Barba M., et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008, (1). CD006649.
15. Sahn S.A. Malignancy metastatic to the pleura. Clin Chest Med 1998, 19(2):351-361.
16. Neragi-Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 2006, 54(1):1-9.
17. Shaw P., Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004, (1). CD002916.
18. Warren W.H., Kalimi R., Khodadadian L.M., et al. Management of malignant pleural effusions using the Pleur(x) catheter. Ann Thorac Surg 2008, 85(3):1049-1055.
19. Tremblay A., Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006, 129(2):362-368.
20. Demmy T. Comparison of in-dwelling catheters and talc pleurodesis in the management of malignant pleural effusions. Presented at ASCO 2010, June 4-8, Chicago, IL.
21. Abraham K.P., Reddy V., Gattuso P. Neoplasms metastatic to the heart: review of 3314 consecutive autopsies. Am J Cardiovasc Pathol 1990, 3(3):195-198.
22. Gornik H.L., Gerhard-Herman M., Beckman J.A. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol 2005, 23(22):5211-5216.
23. Cullinane C.A., Paz I.B., Smith D., et al. Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy. Chest 2004, 125(4):1328-1334.
24. Yoneda K.Y., Hardin K.A., Gandara D.R., et al. Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. Clin Lung Cancer 2006, 8(1 suppl):S31-S35.
25. Graves P.R., Siddiqui F., Anscher M.S., et al. Radiation pulmonary toxicity: from mechanisms to management. Semin Radiat Oncol 2010, 20(3):201-207.
26. Movsas B., Raffin T.A., Epstein A.H., et al. Pulmonary radiation injury. Chest 1997, 111(4):1061-1076.
27. McDonald S., Rubin P., Phillips T.L., et al. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995, 31(5):1187-1203.
28. McCarty M.J., Lillis P., Vukelja S.J. Azathioprine as a steroid-sparing agent in radiation pneumonitis. Chest 1996, 109(5):1397-1400.
29. Muraoka T., Bandoh S., Fujita J., et al. Corticosteroid refractory radiation pneumonitis that remarkably responded to cyclosporin A. Intern Med 2002, 41(9):730-733.
30. Ozturk B., Egehan I., Atavci S., et al. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int J Radiat Oncol Biol Phys 2004, 58(1):213-219.
31. Misirlioglu C.H., Demirkasimoglu T., Kucukplakci B., et al. Pentoxifylline and alpha-tocopherol in prevention of radiation-induced lung toxicity in patients with lung cancer. Med Oncol 2007, 24(3):308-311.
32. Ripamonti C. Management of dyspnea in advanced cancer patients. Support Care Cancer 1999, 7(4):233-243.
33. Tanaka K., Akechi T., Okuyama T., et al. Factors correlated with dyspnea in advanced lung cancer patients: organic causes and what else?. J Pain Symptom Manage 2002, 23(6):490-500.
34. Bruera E., Schmitz B., Pither J., et al. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage 2000, 19(5):357-362.
35. Manning H.L., Schwartzstein R.M. Pathophysiology of dyspnea. N Engl J Med 1995, 333(23):1547-1553.
36. Bausewein C., Farquhar M., Booth S., et al. Measurement of breathlessness in advanced disease: a systematic review. Respir Med 2007, 101(3):399-410.
37. Dorman S., Byrne A., Edwards A. Which measurement scales should we use to measure breathlessness in palliative care?. A systematic review. Palliat Med 2007, 21(3):177-191.
38. Livermore N., Butler J.E., Sharpe L., et al. Panic attacks and perception of inspiratory resistive loads in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 178(1):7-12.
39. Giardino N.D., Curtis J.L., Abelson J.L., et al. The impact of panic disorder on interoception and dyspnea reports in chronic obstructive pulmonary disease. Biol Psychol 2010, 84(1):142-146.
40. Brenes G.A. Anxiety and chronic obstructive pulmonary disease: prevalence, impact, and treatment. Psychosom Med 2003, 65(6):963-970.
41. Ng T.P., Niti M., Tan W.C., et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007, 167(1):60-67.
42. Yellowlees P.M., Alpers J.H., Bowden J.J., et al. Psychiatric morbidity in patients with chronic airflow obstruction. Med J Aust 1987, 146(6):305-307.
43. Fainsinger R.L., Waller A., Bercovici M., et al. A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliat Med 2000, 14(4):257-265.
44. Tanaka K., Akechi T., Okuyama T., et al. Prevalence and screening of dyspnea interfering with daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manage 2002, 23(6):484-489.
45. Henoch I., Bergman B., Gustafsson M., et al. The impact of symptoms, coping capacity, and social support on quality of life experience over time in patients with lung cancer. J Pain Symptom Manage 2007, 34(4):370-379.
46. Gift A.G. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabil Nurs 1989, 14(6):323-325.
47. Borg G.A. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982, 14(5):377-381.
48. Gift A.G., Narsavage G. Validity of the numeric rating scale as a measure of dyspnea. Am J Crit Care 1998, 7(3):200-204.
49. Wilson R.C., Jones P.W. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci (Lond) 1989, 76(3):277-282.
50. Mularski R.A., Campbell M.L., Asch S.M., et al. A review of quality of care evaluation for the palliation of dyspnea. Am J Respir Crit Care Med 2010, 181(6):534-538.
51. Mahler D.A., Selecky P.A., Harrod C.G., et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest 2010, 137(3):674-691.
52. Viola R., Kiteley C., Lloyd N.S., et al. The management of dyspnea in cancer patients: a systematic review. Support Care Cancer 2008, 16(4):329-337.
53. Mazzocato C., Buclin T., Rapin C.H. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Ann Oncol 1999, 10(12):1511-1514.
54. Clemens K.E., Quednau I., Klaschik E. Is there a higher risk of respiratory depression in opioid-naive palliative care patients during symptomatic therapy of dyspnea with strong opioids?. J Palliat Med 2008, 11(2):204-216.
55. Allard P., Lamontagne C., Bernard P., et al. How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients?. A randomized continuous sequential clinical trial. J Pain Symptom Manage 1999, 17(4):256-265.
56. Abernethy A.P., Currow D.C., Frith P., et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003, 327(7414):523-528.
57. Brown S.J., Eichner S.F., Jones J.R. Nebulized morphine for relief of dyspnea due to chronic lung disease. Ann Pharmacother 2005, 39(6):1088-1092.
58. Charles M.A., Reymond L., Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage 2008, 36(1):29-38.
59. Bruera E., Sala R., Spruyt O., et al. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage 2005, 29(6):613-618.
60. Bruera E., MacEachern T., Ripamonti C., et al. Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 1993, 119(9):906-907.
61. Simon S.T., Higginson I.J., Booth S., et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev 2010, (1). CD007354.
62. Navigante A.H., Cerchietti L.C., Castro M.A., et al. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage 2006, 31(1):38-47.
63. Navigante A.H., Castro M.A., Cerchietti L.C. Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. J Pain Symptom Manage 2010, 39(5):820-830.
64. Currow D.C., Abernethy A.P. Potential opioid-sparing effect of regular benzodiazepines in dyspnea: longer duration of studies needed. J Pain Symptom Manage 2010, 40(5):e1-e2. author reply e-4.
65. Clegg A., Young J.B. Which medications to avoid in people at risk of delirium: a systematic review. Age Ageing 2011, 40(1):23-29.
66. Bruera E., Sweeney C., Willey J., et al. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med 2003, 17(8):659-663.
67. Uronis H.E., Currow D.C., McCrory D.C., et al. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis. Br J Cancer 2008, 98(2):294-299.
68. Booth S., Kelly M.J., Cox N.P., et al. Does oxygen help dyspnea in patients with cancer?. Am J Respir Crit Care Med 1996, 153(5):1515-1518.
69. Abernethy A.P., McDonald C.F., Frith P.A., et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 2010, 376(9743):784-793.
70. Bruera E., de Stoutz N., Velasco-Leiva A., et al. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993, 342(8862):13-14.
71. Booth S., Wade R. Oxygen or air for palliation of breathlessness in advanced cancer. J R Soc Med 2003, 96(5):215-218.
72. Galbraith S., Fagan P., Perkins P., et al. Does the use of a handheld fan improve chronic dyspnea?. A randomized, controlled, crossover trial. J Pain Symptom Manage 2010, 39(5):831-838.
73. Clemens K.E., Quednau I., Klaschik E. Use of oxygen and opioids in the palliation of dyspnoea in hypoxic and non-hypoxic palliative care patients: a prospective study. Support Care Cancer 2009, 17(4):367-377.
74. Congleton J., Muers M.F. The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy. Respir Med 1995, 89(4):291-296.
75. Kohara H., Ueoka H., Aoe K., et al. Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. J Pain Symptom Manage 2003, 26(4):962-967.
76. Ahmedzai S.H., Laude E., Robertson A., et al. A double-blind, randomised, controlled phase II trial of Heliox28 gas mixture in lung cancer patients with dyspnoea on exertion. Br J Cancer 2004, 90(2):366-371.
77. Mercadante S., Ferrera P., Villari P., et al. Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med 2009, 12(1):60-63.
78. Cassileth B.R., Deng G.E., Gomez J.E., et al. Complementary therapies and integrative oncology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(suppl 3):340S-354S.
79. Corner J., Plant H., A'Hern R., et al. Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med 1996, 10(4):299-305.
80. Bredin M., Corner J., Krishnasamy M., et al. Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer. BMJ 1999, 318(7188):901-904.
81. Moore S., Corner J., Haviland J., et al. Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial. BMJ 2002, 325(7373):1145.
82. Connors S., Graham S., Peel T. An evaluation of a physiotherapy led non-pharmacological breathlessness programme for patients with intrathoracic malignancy. Palliat Med 2007, 21(4):285-287.
83. Vickers A.J., Feinstein M.B., Deng G.E., et al. Acupuncture for dyspnea in advanced cancer: a randomized, placebo-controlled pilot trial [ISRCTN89462491]. BMC Palliat Care 2005, 4:5.
84. McMillan S.C., Small B.J. Using the COPE intervention for family caregivers to improve symptoms of hospice homecare patients: a clinical trial. Oncol Nurs Forum 2007, 34(2):313-321.
85. Franssen F.M., Broekhuizen R., Janssen P.P., et al. Effects of whole-body exercise training on body composition and functional capacity in normal-weight patients with COPD. Chest 2004, 125(6):2021-2028.
86. Spruit M.A., Gosselink R., Troosters T., et al. Resistance versus endurance training in patients with COPD and peripheral muscle weakness. Eur Respir J 2002, 19(6):1072-1078.
87. Foster S., Thomas H.M. Pulmonary rehabilitation in lung disease other than chronic obstructive pulmonary disease. Am Rev Respir Dis 1990, 141(3):601-604.
88. Knols R., Aaronson N.K., Uebelhart D., et al. Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol 2005, 23(16):3830-3842.
89. Galvao D.A., Newton R.U. Review of exercise intervention studies in cancer patients. J Clin Oncol 2005, 23(4):899-909.
90. Conn V.S., Hafdahl A.R., Porock D.C., et al. A meta-analysis of exercise interventions among people treated for cancer. Support Care Cancer 2006, 14(7):699-712.
91. Temel J.S., Greer J.A., Goldberg S., et al. A structured exercise program for patients with advanced non-small cell lung cancer. J Thorac Oncol 2009, 4(5):595-601.
92. Lowe S.S., Watanabe S.M., Courneya K.S. Physical activity as a supportive care intervention in palliative cancer patients: a systematic review. J Support Oncol 2009, 7(1):27-34.
93. Adamsen L., Midtgaard J., Rorth M., et al. Feasibility, physical capacity, and health benefits of a multidimensional exercise program for cancer patients undergoing chemotherapy. Support Care Cancer 2003, 11:707-716.
94. French C.L., Irwin R.S., Curley F.J., et al. Impact of chronic cough on quality of life. Arch Intern Med 1998, 158(15):1657-1661.
95. Irwin R.S., French C.T., Fletcher K.E. Quality of life in coughers. Pulm Pharmacol Ther 2002, 15(3):283-286.
96. Wang X.S., Shi Q., Lu C., et al. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer 2010, 116(1):137-145.
97. Homsi J., Walsh D., Nelson K.A. Important drugs for cough in advanced cancer. Support Care Cancer 2001, 9(8):565-574.
98. Luporini G., Barni S., Marchi E., et al. Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer. Eur Respir J 1998, 12(1):97-101.
99. Homsi J., Walsh D., Nelson K.A., et al. A phase II study of hydrocodone for cough in advanced cancer. Am J Hosp Palliat Care 2002, 19(1):49-56.
100. Doona M., Walsh D. Benzonatate for opioid-resistant cough in advanced cancer. Palliat Med 1998, 12(1):55-58.
101. Moroni M., Porta C., Gualtieri G., et al. Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients. Br J Cancer 1996, 74(2):309-311.
102. Trovo M., Linda A., El Naqa I., et al. Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT). Lung Cancer 2010, 69(1):77-85.
103. O'Donnell A.E. Bronchiectasis. Chest 2008, 134(4):815-823.
104. Uzun O., Atasoy Y., Findik S., et al. A prospective evaluation of hemoptysis cases in a tertiary referral hospital. Clin Respir J 2010, 4(3):131-138.
105. Hirshberg B., Biran I., Glazer M., et al. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997, 112(2):440-444.
106. Skaug K., Eide G.E., Gulsvik A. Prevalence and predictors of symptoms in the terminal stage of lung cancer: a community study. Chest 2007, 131(2):389-394.
107. Miller R.R., McGregor D.H. Hemorrhage from carcinoma of the lung. Cancer 1980, 46(1):200-205.
108. Wang G.R., Ensor J.E., Gupta S., et al. Bronchial artery embolization for the management of hemoptysis in oncology patients: utility and prognostic factors. J Vasc Interv Radiol 2009, 20(6):722-729.
109. Ernst A., Silvestri G.A., Johnstone D. Interventional pulmonary procedures: guidelines from the American College of Chest Physicians. Chest 2003, 123(5):1693-1717.
110. Temel J.S., Greer J.A., Muzikansky A., et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010, 363(8):733-742.